Electromed Stock Price, News & Analysis

Electromed (NYSE American: ELMD), a leader in innovative airway clearance technologies, will be added to both the Russell 2000® Index and the Russell 3000® Index effective June 27, 2025. The inclusion comes as part of FTSE Russell's 2025 annual reconstitution, based on preliminary additions announced May 23, 2025.

The Russell 3000 Index encompasses the largest 3,000 U.S. public companies by market cap, while the Russell 2000 Index is its small-cap subset. These indices serve as key benchmarks for institutional investors and index funds, with approximately $10.6 trillion in assets benchmarked against Russell US Indexes.

Electromed (NYSE American: ELMD) reported strong Q3 FY 2025 financial results, marking its tenth consecutive quarter of year-over-year revenue and net income growth. Net revenue increased 13.1% to $15.7 million, with operating income rising 16.2% to $2.1 million. Net income grew to $1.9 million ($0.21 per diluted share), up from $1.5 million ($0.17 per diluted share) year-over-year. The company's direct homecare business saw a 14.8% increase to $14.1 million. Operating cash flow improved to $7.5 million for the nine months ended Q3 FY 2025. The board approved a $5M stock repurchase authorization. As of March 31, 2025, Electromed maintained a strong financial position with $15.2 million in cash, $23.4 million in accounts receivable, and no debt.

Electromed (NYSE American: ELMD), a leader in innovative airway clearance technologies, has scheduled its fiscal 2025 third quarter financial results announcement for May 13, 2025.

The company will release its financial results for the quarter ended March 31, 2025, after the stock market closes. Management will host a conference call at 5:00 p.m. Eastern Time on the same day to discuss the results.

Investors can participate through:

• Domestic dial-in: (844) 826-3033
• International dial-in: (412) 317-5185
• Live webcast: Available in the Investor Relations section of Electromed's website

For those unable to attend live, a replay will be available via:

• Domestic replay: (844) 512-2921
• International replay: (412) 317-6671
• Replay Access ID: 10199555
• Online replay: Available in the Investor Relations section under Events & Presentations

Electromed (NYSE American: ELMD) has announced its participation in the 15th Annual LD Micro Invitational, scheduled for April 9-10, 2025, at the Westin Grand Central in New York. Jim Cunniff, President and CEO, will present on April 10 at 2:30 PM ET.

The event will showcase 50+ companies and features:

• Registration starting April 9 at 2:00 PM ET
• Keynote presentations
• CBIZ Offices Rooftop happy hour
• Company presentations beginning April 10 at 8:00 AM ET
• LD Micro Moneyball Afterparty at the Knickerbocker Hotel

Interested investors can access the live webcast of the presentation through the event registration link: https://ldinv15.sequireevents.com/

Electromed (NYSE American: ELMD) announced that its board of directors has authorized a new share repurchase program of up to $5.0 million of common stock on March 6, 2025. The company, which specializes in innovative airway clearance technologies, will execute the buyback through various means including open market purchases, private transactions, and block trades, depending on market conditions.

Management will determine the timing and volume of repurchases based on market conditions and other factors. The board will periodically review and may modify the authorization's terms and size. CEO Jim Cunniff stated that this initiative demonstrates confidence in their business strength and commitment to creating shareholder value while maintaining financial flexibility for future growth investments.

Electromed (NYSE American: ELMD), a leader in innovative airway clearance technologies, has announced its participation in two upcoming investor conferences.

The company will present at the Oppenheimer 35th Annual Healthcare MedTech and Services Virtual Conference on Tuesday, March 18, 2025, at 10:30 a.m. Eastern Time. Additionally, management will present at the Sidoti Virtual Small-Cap Conference on Thursday, March 20, 2025, at 1:45 p.m. Eastern Time.

Live and archived webcasts for both events will be accessible through the Electromed website under Events & Presentations. For the Oppenheimer conference, investors can request meetings through their Oppenheimer representative.

Electromed (NYSE American: ELMD) reported record financial results for Q2 FY 2025. Net revenue increased 18.7% to $16.3 million, while operating income reached $2.5 million (15.6% of net revenues). Net income grew to $2.0 million ($0.22 per diluted share), up from $1.7 million ($0.19 per diluted share) in Q2 FY 2024.

The company's direct homecare business saw a 15.2% increase to $14.6 million, driven by increased referrals and approvals. The field sales force expanded to 60 employees, with 54 direct sales representatives. Gross profit improved to 77.7% of net revenues ($12.6 million). As of December 31, 2024, Electromed maintained a strong financial position with $16.2 million in cash, $22.8 million in accounts receivable, and no debt.

Electromed (NYSE American: ELMD), a leader in innovative airway clearance technologies, has announced it will release its fiscal 2025 second quarter financial results on February 11, 2025, after market close. The company will host a conference call at 5:00 p.m. Eastern Time on the same day to discuss the results.

Investors can join the call by dialing (844) 826-3033 (Domestic) or (412) 317-5185 (International). A live webcast will be available in the Investor Relations section of Electromed's website. For those unable to attend, a replay will be accessible via phone using replay pin 10196088 or through the company's website.

Electromed, a leader in airway clearance technologies, announced its fiscal Q1 2025 financial results. Net revenue rose by 19.0% to $14.7 million, with gross margin improving to 78.3%. Operating income increased to $1.9 million, and net income surged to $1.5 million, or $0.16 per diluted share. The company repurchased 262,756 shares at an average price of $17.26, totaling approximately $4.5 million. Electromed continues to invest in growth initiatives, including the expansion of its direct sales force to 53 reps and the launch of a new marketing campaign. Cash balance decreased by $2.2 million, primarily due to share repurchases, leaving $13.9 million in cash and no debt. The company achieved a working capital of $33.6 million.